Skip to main content

Table 3 Patients characteristics according to each risk factor with or without prior myocardial infarction (PMI)

From: The ratio of serum n-3 to n-6 polyunsaturated fatty acids is associated with diabetes mellitus in patients with prior myocardial infarction: a multicenter cross-sectional study

 

HTN

DL

DM

PMI +

PMI-

P value

PMI+

PMI-

P value

PMI+

PMI-

P value

n

225

1039

 

245

973

 

144

533

 

Age, y.o

65.0 ± 10.5

65.7 ± 10.8

0.35

63.7 ± 10.5

64.6 ± 10.9

0.4

64.9 ± 10.1

66.8 ± 10.1

<0.05

Male, n

201 (89.3%)

774 (74.5%)

<0.001

217 (88.6%)

731 (75.1%)

<0.0001

125 (86.8%)

433 (80.9%)

0.11

BMI, kg/m2

24.8 ± 3.4

24.7 ± 3.6

0.58

24.9 ± 3.5

24.7 ± 3.5

0.45

24.4 ± 3.3

24.8 ± 3.8

0.25

HTN, n

-

-

 

188 (76.7%)

730 (75.0%)

0.62

110 (76.4%)

417 (77.9%)

0.74

DM, n

188 (83.6%)

730 (70.3%)

<0.001

-

-

 

118 (81.9%)

410 (76.6%)

0.21

DL, n

110 (48.9%)

417 (40.1%)

0.02

118 (48.2%)

410 (42.1%)

0.1

-

-

 

Smoking, n

106 (47.1%)

448 (43.1%)

0.3

117 (47.8%)

454 (46.7%)

0.77

72 (50.0%)

268 (50.1%)

0.98

FH, n

56 (24.9%)

186 (17.9%)

0.016

54 (22.0%)

188 (19.3%)

0.37

36 (25.0%)

117 (21.9%)

0.43

eGFRa, ml/min/1.73 m2

66.5 ± 18.2

67.4 ± 17.6

0.49

66.9 ± 19.5

68.3 ± 17.1

0.32

69.5 ± 19.9

68.3 ± 18.6

0.54

LDL, mg/dL

101.4 ± 28.7

110.8 ± 29.7

<0.0001

103.3 ± 30.2

114.0 ± 32.3

<0.0001

103.3 ± 30.3

110.3 ± 29.4

0.02

TGL, mg/dL

151.7 ± 94.9

148.8 ± 89.6

0.69

154.6 ± 93.4

158.7 ± 103.4

0.61

155.3 ± 107.5

151.9 ± 89.2

0.72

HbA1cb, %

6.0 ± 1.1

5.9 ± 1.1

0.12

6.0 ± 1.3

5.9 ± 1.1

0.34

6.7 ± 1.4

6.7 ± 1.2

0.76

UAc, mg/dL

6.1 ± 1.3

5.9 ± 1.4

0.11

6.1 ± 1.3

5.8 ± 1.4

0.11

6.0 ± 1.5

5.8 ± 1.3

0.37

BNPd, pg/mL

78.9 ± 119.3

49.8 ± 69.1

<0.01

83.9 ± 165.8

42.9 ± 54.2

<0.001

75.0 ± 133.2

54.4 ± 65.7

0.16

hs-CRP, mg/dL

0.26 ± 0.64

0.23 ± 0.67

0.59

0.21 ± 0.54

0.25 ± 0.73

0.56

0.31 ± 0.73

0.30 ± 0.91

0.87

Statin, n

167 (74.2%)

551 (53.0%)

<0.001

194 (79.2%)

633 (65.1%)

<0.001

111 (77.1%)

314 (58.7%)

<0.0001

BB, n

113 (50.2%)

443 (42.6%)

0.04

118 (48.2%)

376 (38.7%)

<0.01

74 (51.4%)

235 (43.9%)

0.13

ARBor ACEi, n

158 (70.2%)

628 (60.4%)

<0.01

157 (64.1%)

479 (49.2%)

<0.0001

96 (66.7%)

281 (52.5%)

<0.01

EPA, μg/mL

69.3 ± 36.5

75.1 ± 43.0

0.06

68.4 ± 36.2

76.4 ± 44.6

<0.01

64.8 ± 33.1

75.5 ± 40.6

<0.005

DHA, μg/mL

135.8 ± 47.8

145.8 ± 51.4

<0.01

136.3 ± 49.8

149 ± 54.3

<0.001

128.9 ± 41.1

143.1 ± 50.4

<0.005

AA, μg/mL

153.4 ± 38.3

156.2 ± 40.8

0.35

157.4 ± 39.1

162.7 ± 43.0

0.08

154.4 ± 39.9

154.1 ± 41.3

0.75

DHLA, μg/mL

32.3 ± 11.9

33.5 ± 12.5

0.22

33.7 ± 11.9

34.9 ± 12.6

0.16

32.5 ± 11.6

33.5 ± 12.7

0.43

EPA/AA

0.47 ± 0.27

0.50 ± 0.30

0.19

0.46 ± 0.28

0.49 ± 0.29

0.21

0.45 ± 0.26

0.52 ± 0.29

<0.01

DHA/AA

0.92 ± 0.35

0.97 ± 0.35

0.06

0.91 ± 0.36

0.95 ± 0.34

0.06

0.88 ± 0.32

0.97 ± 0.33

<0.005

EPA + DHA/AA + DHLA

1.15 ± 0.03

1.22 ± 0.02

0.88

1.13 ± 0.49

1.19 ± 0.49

0.08

1.09 ± 0.44

1.22 ± 0.49

<0.005

  1. Continuous variables are presented as means ± standard deviations. Categorical variables are presented as percentages. Abbreviations are listed in the footnote to Table 1. anumbers of patients were 183 vs. 823, 201 vs. 736, and 119 vs. 416 (HTN with vs. without PMI, DL with vs. without PMI, and DM with vs. without PMI, respectively), bnumbers of patients were 181 vs. 809, 200 vs. 728, and 118 vs. 418 (same as above), cnumbers of patients were 91 vs. 450, 95 vs. 373, and 46 vs. 168 (same as above), dnumbers of patients were 87 vs. 412, 90 vs. 334, and 44 vs. 152 (same as above)
Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us